Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The benefits become partially offset by the detriments
Product Specifications
Introduction and Background GLP-1 receptor agonists have revolutionized diabetes and obesity care with dramatic efficacy
Weight loss Blood sugar control Anti-inflammatory Cardioprotective Nephroprotective Weight Loss Semaglutide induces lipolysis by reducing blood sugar levels and thus enhancing fatty acid oxidation
In fact, research shows that nearly two-thirds of GLP-1 users may fall short on calcium
MASH resolution without worsening of fibrosis: 2.4 mg dose: 47% of participants (vs 14% placebo) 4.8 mg dose: 62% of participants (vs 14% placebo) 6.0 mg dose: 43% of participants (vs 14% placebo) Liver fat reduction of at least 30%: 2.4 mg dose: 63% of participants 4.8 mg dose: 67% of participants 6.0 mg dose: 57% of participants Placebo: 14% of participants Fibrosis improvement by at least one stage: Survodutide groups: 34-36% Placebo: 22% The percentage change from baseline in liver fat content after 48 weeks was a staggering 62% reduction in the 6.0 mg group, compared to just 5.7% in the placebo group
